Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model
Hiromitsu Watanabe(Hamamatsu University School of Medicine), Hideaki Miyake(Kobe University)
Cited by 7
Related Papers
Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma
|Anticancer Research|2020|8